GAD treatment and insulin secretion in recent-onset type 1 diabetes.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  New England Journal of Medicine

• Publication date

  2008-10-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa0804328PMID 18843118
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes

  2008cited by this paper
• Heat‐shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double‐blind phase II study

  2007cited by this paper
• A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

  2005cited by this paper
• Diabetes-associated HLA genotypes affect birthweight in the general population

  2005cited by this paper
• Immunomodulation with human recombinant autoantigens.

  2005cited by this paper
• The Prospect of Vaccination to Prevent Type 1 Diabetes

  2005cited by this paper
• Insulin as a Primary Autoantigen for Type 1A Diabetes

  2005cited by this paper
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

  2005cited by this paper
• Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.

  2005cited by this paper
• Insulin secretion in type 1 diabetes.

  2004cited by this paper
• Diabetes Therapeutics News

  2003cited by this paper
• Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes.

  2002cited by this paper
• Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.

  2001cited by this paper
• Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double‐blind placebo‐controlled study

  2001cited by this paper
• Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial

  2001cited by this paper
• Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

  2001cited by this paper
• Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

  2001cited by this paper
• β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

  2001cited by this paper
• Role of C-peptide in human physiology.

  2000cited by this paper
• Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial

  1998cited by this paper
• Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice.

  1998cited by this paper
• Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes–prone mice

  1996cited by this paper
• Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).

  1995cited by this paper
• Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study)

  1995cited by this paper
• Declining incidence of nephropathy in insulin-dependent diabetes mellitus.

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Randomisation and baseline comparisons in clinical trials.

  1990cited by this paper
• A trial of nicotinamide in newly diagnosed patients with Type 1 (insulin-dependent) diabetes mellitus

  1990cited by this paper
• Clinical trials of cyclosporin in IDDM.

  1988cited by this paper
• Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control.

  1987cited by this paper
• Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.

  1985cited by this paper
• Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children.

  1983cited by this paper
• Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins

  1982cited by this paper

• Novel Therapeutic Approach to Preserving or Reversing Pancreatic Islet Beta Cells in Patients With Type 1 Diabetes: A Bayesian Network Meta‐Analysis of Comparative Efficacy

  2026cites this paper
• Immunotherapies for prevention and treatment of type 1 diabetes

  2025cites this paper
• Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial

  2025cites this paper
• The future of type 1 diabetes therapy.

  2025cites this paper
• Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes

  2025cites this paper
• Exploring the progress and trends of immunotherapy for type 1 diabetes: A comprehensive bibliometric analysis spanning nearly two decades

  2025cites this paper
• New Perspectives in Studying Type 1 Diabetes Susceptibility Biomarkers

  2025cites this paper
• Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians

  2025cites this paper
• Regulatory T cell-based therapies for type 1 diabetes: a narrative review

  2025cites this paper
• Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments

  2025influential citation
• Revolutionizing Diabetes Management: A Comparative Analysis of Novel Vaccine Therapies with Conventional Treatments

  2025cites this paper
• (TCRαβ+) Double-Negative T Cells in Type 1 Diabetes Mellitus

  2025cites this paper
• Leveraging circulating microRNAs for personalized disease-modifying therapies in type 1 diabetes.

  2025cites this paper
• LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice.

  2024cites this paper
• Immunotherapy for Type 1 Diabetes: Mechanistic Insights and Impact of Delivery Systems.

  2024cites this paper
• Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes

  2024cites this paper
• Dendritic cells and antigen-specific immunotherapy in autoimmune rheumatic diseases.

  2024cites this paper
• From islet transplantation to beta-cell regeneration: an update on beta-cell-based therapeutic approaches in type 1 diabetes

  2024cites this paper
• Reversal of diabetes by an oral Salmonella-based vaccine in acute and progressive diabetes in NOD mice

  2024cites this paper
• The Immunology of type 1 diabetes

  2024cites this paper
• Strategies and delivery systems for cell-based therapy in autoimmunity

  2024cites this paper
• [Immunotherapy of type 1 diabetes mellitus].

  2024cites this paper
• Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial

  2024cites this paper
• Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial

  2023cites this paper
• MESA 3: PRESENTE Y FUTURO DE LAS TERAPIAS BIOLÓGICAS PARA EL TRATAMIENTO DE LA DIABETES MELLITUS TIPO 1

  2023cites this paper
• Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial

  2023cites this paper
• A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes

  2023cites this paper
• HLA‐DR3 mediated CD4 T cell response against GAD65 in type 1 diabetes patients

  2023cites this paper
• A 1‐year pilot study of intralymphatic injections of GAD‐alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes

  2023cites this paper
• Type 1 diabetes: key drug targets and how they could influence future therapeutics

  2023cites this paper
• Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype

  2023cites this paper
• GABA and Combined GABA with GAD65-Alum Treatment Alters Th1 Cytokine Responses of PBMCs from Children with Recent-Onset Type 1 Diabetes

  2023cites this paper
• The need and benefit of immune monitoring to define patient and disease heterogeneity, mechanisms of therapeutic action and efficacy of intervention therapy for precision medicine in type 1 diabetes

  2023cites this paper
• Monitoring immunomodulation strategies in type 1 diabetes

  2023cites this paper
• From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes

  2022influential citation
• Antigen-specific immunotherapy to restore antigen-specific tolerance in Type 1 diabetes and Graves’ disease

  2022cites this paper
• Latent Autoimmune Diabetes in Adults: Background, Safety and Feasibility of an Ongoing Pilot Study With Intra-Lymphatic Injections of GAD-Alum and Oral Vitamin D

  2022cites this paper
• A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes

  2022cites this paper
• Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes

  2022cites this paper
• Particle-Based therapies for antigen specific treatment of type 1 diabetes.

  2022cites this paper
• Self-Antigens Targeted by Regulatory T Cells in Type 1 Diabetes

  2022cites this paper
• Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes

  2022cites this paper
• Glutamic acid decarboxylase immunotherapy for type 1 diabetes

  2022cites this paper
• Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: A central role for alum as adjuvant

  2022cites this paper
• Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes

  2022cites this paper
• Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic

  2022cites this paper
• Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)

  2022cites this paper
• Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions Clinical Applications and Challenges with its Definitions

  2022cites this paper
• Gluten peptide immunomodulatory strategies

  2021cites this paper
• Epigenetic Changes Induced by Maternal Factors during Fetal Life: Implication for Type 1 Diabetes

  2021cites this paper
• Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity

  2021influential citation
• Novel delivery mechanisms for antigen-specific immunotherapy

  2021cites this paper
• An Insulin‐Inspired Supramolecular Hydrogel for Prevention of Type 1 Diabetes

  2021cites this paper
• Biophysical Properties of Self-Assembled Immune Signals Impact Signal Processing and the Nature of Regulatory Immune Function.

  2021cites this paper
• Combined Etanercept, GAD‐alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes

  2021cites this paper
• Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases

  2021cites this paper
• Immune response differs between intralymphatic or subcutaneous administration of GAD‐alum in individuals with recent onset type 1 diabetes

  2021cites this paper
• The Effect of Immunosuppressive Adjuvant Kynurenine on Type 1 Diabetes Vaccine

  2021cites this paper
• Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial

  2021cites this paper
• Clinical trials of promising apoptosis modulating drugs

  2021cites this paper
• Partial Clinical Remission Reduces Lipid-Based Cardiovascular Risk in Adult Patients With Type 1 Diabetes

  2021cites this paper
• Introduction: specific disease areas

  2021cites this paper
• Biomaterial strategies to treat autoimmunity and unwanted immune responses to drugs and transplanted tissues

  2021cites this paper
• Autoantibodies to N-terminally Truncated GAD65(96-585): HLA Associations and Predictive Value for Type 1 Diabetes

  2021cites this paper
• Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

  2020cites this paper
• Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial

  2020cites this paper
• Post-translational modifications contribute to neoepitopes in Type-1 diabetes: Challenges for inducing antigen-specific tolerance.

  2020cites this paper
• Linking autoantigen properties to mechanisms of immunity.

  2020cites this paper
• Polyvalent therapeutic vaccine for type 2 diabetes mellitus: Immunoinformatics approach to study co-stimulation of cytokines and GLUT1 receptors

  2020cites this paper
• New era of therapy for endocrine autoimmune disorders

  2020cites this paper
• Recurrence of type 1 diabetes following simultaneous pancreas-kidney transplantation

  2020cites this paper
• Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route

  2020cites this paper
• Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview

  2020cites this paper
• Administration of metrnl delays the onset of diabetes in non-obese diabetic mice.

  2020cites this paper
• Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)

  2020cites this paper
• The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases

  2020cites this paper
• Immunotherapy for Autoimmune Diseases

  2020cites this paper
• Tolerance-inducing medicines in autoimmunity: rheumatology and beyond.

  2020cites this paper
• Type 1 Diabetes Mellitus

  2020cites this paper
• Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients

  2020influential citation
• European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2

  2020cites this paper
• Prevention of Autoimmune Disease: The Type 1 Diabetes Paradigm

  2020cites this paper
• Therapeutic Effects of BCG Vaccination on Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2020cites this paper
• Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities

  2020cites this paper
• Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes

  2020cites this paper
• A Question of Tolerance—Antigen-Specific Immunotherapy for Type 1 Diabetes

  2020cites this paper
• Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions.

  2019cites this paper
• Analysis of covariance in randomized trials: More precision and valid confidence intervals, without model assumptions

  2019cites this paper
• Pediatric Diabetes: Review Article

  2019cites this paper
• 5．生活習慣病を標的とした抗体誘導型ワクチンの トランスレーショナルリサーチ

  2019cites this paper
• Antigen-specific therapeutic approaches for autoimmunity

  2019cites this paper
• [Development of therapeutic vaccine for life style-related diseases].

  2019cites this paper
• Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine.

  2019cites this paper
• Evaluation of the feasibility of intralymphatic injection of Diamyd

  2019cites this paper
• Physiopathologie des états diabétiques

  2019cites this paper
• Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology.

  2019cites this paper
• Diabetes Mellitus

  2019cites this paper
• Immune Intervention for Type 1 Diabetes

  2018influential citation
• Opuntia stricta Cladode Extract Reduces Blood Glucose Levels in Alloxan-induced Diabetic Mice

  2018cites this paper
• Type 1 Diabetes Recurrence After Simultaneous Pancreas-Kidney Transplantation

  2018cites this paper